SATO VICKI L 4

What Happened

• Vicki L. Sato, a director of Vir Biotechnology, sold 22,000 shares on February 2, 2026. The reported weighted-average sale price was $7.71 per share, for aggregate proceeds of approximately $169,671. The filing reports the sale as an open-market or private sale (Form 4 code S) and notes the transactions were executed under a Rule 10b5-1 trading plan adopted by Ms. Sato on March 27, 2025.
• This is a sale (not a purchase); sales executed under pre-arranged 10b5-1 plans are common and typically considered routine rather than a direct signal of the insider’s view.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-03 (timely).
• Shares sold: 22,000; weighted-average price: $7.71; total proceeds: ~$169,671.
• Price range reported: $7.32 to $7.82 (shares sold in multiple trades). The filer will provide per-price breakdown on request (per footnote).
• Footnote: Sale effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2025.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• 10b5-1 trading plans allow insiders to sell shares according to a pre-set schedule and help avoid accusations of trading on non-public information; such sales are often routine.
• For retail investors, purchases typically carry more informational weight than routine sales; treat this transaction as a disclosed, plan-driven sale unless additional context (e.g., changes in ownership level) is disclosed later.